Inclusion Criteria

Inclusion criteria:

- Patients with histologically or cytologically confirmed diagnosis of advanced, non
resectable and/or metastatic, relapsed or refractory solid tumours not amenable to
standard therapy and for whom no therapy of proven efficacy exists

- Eastern Cooperative Oncology Group performance score 0 - 2

- Recovery from clinically significant toxicities from previous systemic anti-cancer
therapies or radiotherapy

Exclusion criteria:

- Serious illness, concomitant non-oncological disease or mental problem considered by
the investigator to be incompatible with participation to the trial

- Known hypersensitivity to the trial drugs or their excipients

- Treatment with any other investigational drug or active participation in any other
interventional trial within 28 days before first administration of trial drug(s) or
concomitantly with this trial

- Major surgery or radiotherapy within 28 days before start of therapy or concomitantly
with this trial

- Systemic anti-cancer therapy within 28 days before start of therapy or concomitantly
with this trial

- Requirements for treatment with any of the prohibited concomitant medications

- Active infectious disease or known HIV I/II infection

- Gastrointestinal disorders that may interfere with the absorption of the study drug
or chronic diarrhoea

- Active brain metastases

- History or presence of cardiovascular abnormalities deemed clinically relevant by the
investigator

- Cardial left ventricular function with resting ejection fraction < 50%

- Inadequate hepatic, renal and haematologic organ function

- QT prolongation deemed clinically relevant by the investigator

- Active alcohol or drug abuse

- Women of childbearing potential and men who are able to father a child unwilling to
use a medically acceptable method of contraception during the trial and 28 days
thereafter

- Pregnancy or breast-feeding

- Patients unable to comply with the protocol

- Patients with known pre-existing interstitial lung disease